ELEVATED SERUM GAMMA-GLUTAMYLTRANSFERASE IS AN ADVERSE PROGNOSTIC FACTOR IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE

被引：0
|
作者：
Takemura, Kosuke
Ito, Masaya
Nakanishi, Yasukazu
Kataoka, Madoka
Sakamoto, Kazumasa
Suzuki, Hiroaki
Iida, Noriyuki
Tobisu, Ken-ichi
Koga, Fumitaka
机构：
来源：
JOURNAL OF UROLOGY | 2019年 / 201卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP28-11
引用
收藏
页码：E407 / E408
页数：2
相关论文
共 50 条
  • [31] The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel
    Bourdoumis, Andreas
    Chrisofos, Michael
    Stasinou, Theodora
    Christopoulos, Panagiotis
    Mourmouris, Panagiotis
    Kostakopoulos, Athanasios
    Deliveliotis, Charalambos
    ANTICANCER RESEARCH, 2015, 35 (05) : 3075 - 3079
  • [32] Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study
    Benoist, Guillemette E.
    van Oort, Inge M.
    Boerrigter, Emmy
    Verhaegh, Gerald W.
    van Hooij, Onno
    Groen, Levi
    Smit, Frank
    de Mol, Pieter
    Hamberg, Paul
    Dezentje, Vincent O.
    Mehra, Niven
    Gerritsen, Winald
    Somford, Diederik M.
    van Erp, Nielka P. H.
    Schalken, Jack A.
    CLINICAL CHEMISTRY, 2020, 66 (06) : 842 - 851
  • [33] Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide
    Caffo, Orazio
    Basso, Umberto
    Cattrini, Carlo
    Ermacora, Paola
    Maruzzo, Marco
    Alberti, Martina
    Anesi, Cecilia
    Bimbatti, Davide
    Cani, Massimiliano
    Crespi, Veronica
    Farinea, Giovanni
    Kadrija, Dzenete
    Kinspergher, Stefania
    Lai, Eleonora
    Lay, Ludovica
    Maines, Francesca
    Mennitto, Alessia
    Pierantoni, Francesco
    Samuelly, Alessandro
    Urban, Susanna
    Buttigliero, Consuelo
    Veccia, Antonello
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [34] Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
    Tucci, Marcello
    Zichi, Clizia
    Buttigliero, Consuelo
    Vignani, Francesca
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    ONCOTARGETS AND THERAPY, 2018, 11 : 7353 - 7368
  • [35] Natural killer cell activity in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
    Zedan, Ahmed
    Nederby, Line
    Volmer, Lone
    Madsen, Christine Vestergaard
    Sorensen, Bente E.
    Hansen, Torben
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [36] Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Hoang, Anh
    Karlou, Maria
    Ashe, Robynne
    Tu, Shi Ming
    Aparicio, Ana
    Troncoso, Patricia
    Mohler, James
    Logothetis, Christopher J.
    EUROPEAN UROLOGY, 2015, 67 (01) : 53 - 60
  • [37] Short-termoutcome of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Tamada, Satoshi
    Iguchi, Taro
    Tachibana, Hirokazu
    Nakatani, Tatsuya
    ANNALS OF ONCOLOGY, 2015, 26 : 145 - 146
  • [38] Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
    Schrader, Andres Jan
    Boegemann, Martin
    Ohlmann, Carsten-H.
    Schnoeller, Thomas J.
    Krabbe, Laura-Maria
    Hajili, Turkan
    Jentzmik, Florian
    Stoeckle, Michael
    Schrader, Mark
    Herrmann, Edwin
    Cronauer, Marcus V.
    EUROPEAN UROLOGY, 2014, 65 (01) : 30 - 36
  • [39] Comparison of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan
    Ni, Hsueh Fen
    Li, Jian-Ri
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 60 - 60
  • [40] Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
    Rhea, Logan P.
    Gupta, Brinda
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (02) : 107 - 108
12345